3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE

Richard Elliott; Alan Ashworth; Christopher J Lord; Dan Niculescu-Duvaz; Roderick Porter; Raymond Boffey; Melanie Bayford; Stuart Firth-Clark; Ashley Jarvis; Trevor R Perrior; Rebecca Key

3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE

Richard Elliott (Inventor), Alan Ashworth (Inventor), Christopher J Lord (Inventor), Dan Niculescu-Duvaz (Inventor), Roderick Porter (Inventor), Raymond Boffey (Inventor), Melanie Bayford (Inventor), Stuart Firth-Clark (Inventor), Ashley Jarvis (Inventor), Trevor R Perrior (Inventor), Rebecca Key (Inventor)

Research output: Patent

Abstract / Description of output

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3-aryl-5-substituted- 2H-isoquinolin-1-one compounds that, inter alia, inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.) and/or Wnt signalling. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to inhibit Wnt signalling; to treat disorders that are ameliorated by the inhibition of PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to treat disorders that are ameliorated by the inhibition of Wnt signalling; to treat proliferative conditions such as cancer, etc.
(FR) La présente invention concerne d'une manière générale le domaine des composés thérapeutiques. Plus spécifiquement, la présente invention se rapporte à certains composés 3-aryl -5-substitué -2 H-isoquinolin -1-one qui, entre autres, inhibent PARP (par exemple, PARP1, TNKS1, TNKS2, etc.) et/ou de signalisation Wnt. La présente invention concerne également des compositions pharmaceutiques comprenant ces composés à la fois in vitro et in vivo pour inhiber la signalisation Wnt afin de traiter des troubles qui sont améliorés par l'inhibition de PARP (par exemple, PARP1, TNKS1, TNKS2, etc.), de traiter des troubles qui sont améliorés par l'inhibition de la signalisation Wnt et de traiter des états prolifératifs tels que le cancer, etc.

Original language	English
Patent number	WO2013132253
IPC	A61P 35/00 (2006.01) ,A61K 31/472 (2006.01) ,C07D 401/14 (2006.01) ,C07D 217/14 (2006.01) ,C07D 217/16 (2006.01) ,C07D 401/04 (2006.01) ,C07D 401/10 (2006.01) ,C07D 401/12 (2006.01) ,C07D 405/12 (2006.01) ,C07D 487/04 (2006.01) ,C07D 487/08 (2006.01) ,C07D 487/10 (2006.01) ,A61K 31/4725 (2006.01) ,A61K 31/496 (2006.01) ,A61K 31/506 (2006.01)
Priority date	7/03/12
Filing date	7/03/13
Publication status	Published - 12 Sept 2013

Access to Document

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2013132253

Cite this

Elliott, R., Ashworth, A., Lord, C. J., Niculescu-Duvaz, D., Porter, R., Boffey, R., Bayford, M., Firth-Clark, S., Jarvis, A., Perrior, T. R., & Key, R. (2013). 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE. (Patent No. WO2013132253). World Intellectual Property Organisation. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2013132253

@misc{ddae64af65fb4fc184a5ff78cdbcf3c5,

title = "3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE",

abstract = "The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3-aryl-5-substituted- 2H-isoquinolin-1-one compounds that, inter alia, inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.) and/or Wnt signalling. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to inhibit Wnt signalling; to treat disorders that are ameliorated by the inhibition of PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to treat disorders that are ameliorated by the inhibition of Wnt signalling; to treat proliferative conditions such as cancer, etc.(FR) La pr{\'e}sente invention concerne d'une mani{\`e}re g{\'e}n{\'e}rale le domaine des compos{\'e}s th{\'e}rapeutiques. Plus sp{\'e}cifiquement, la pr{\'e}sente invention se rapporte {\`a} certains compos{\'e}s 3-aryl -5-substitu{\'e} -2 H-isoquinolin -1-one qui, entre autres, inhibent PARP (par exemple, PARP1, TNKS1, TNKS2, etc.) et/ou de signalisation Wnt. La pr{\'e}sente invention concerne {\'e}galement des compositions pharmaceutiques comprenant ces compos{\'e}s {\`a} la fois in vitro et in vivo pour inhiber la signalisation Wnt afin de traiter des troubles qui sont am{\'e}lior{\'e}s par l'inhibition de PARP (par exemple, PARP1, TNKS1, TNKS2, etc.), de traiter des troubles qui sont am{\'e}lior{\'e}s par l'inhibition de la signalisation Wnt et de traiter des {\'e}tats prolif{\'e}ratifs tels que le cancer, etc.",

author = "Richard Elliott and Alan Ashworth and Lord, {Christopher J} and Dan Niculescu-Duvaz and Roderick Porter and Raymond Boffey and Melanie Bayford and Stuart Firth-Clark and Ashley Jarvis and Perrior, {Trevor R} and Rebecca Key",

year = "2013",

month = sep,

day = "12",

language = "English",

publisher = "World Intellectual Property Organisation",

type = "Patent",

note = "WO2013132253; A61P 35/00 (2006.01) ,A61K 31/472 (2006.01) ,C07D 401/14 (2006.01) ,C07D 217/14 (2006.01) ,C07D 217/16 (2006.01) ,C07D 401/04 (2006.01) ,C07D 401/10 (2006.01) ,C07D 401/12 (2006.01) ,C07D 405/12 (2006.01) ,C07D 487/04 (2006.01) ,C07D 487/08 (2006.01) ,C07D 487/10 (2006.01) ,A61K 31/4725 (2006.01) ,A61K 31/496 (2006.01) ,A61K 31/506 (2006.01)",

}

TY - PAT

T1 - 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE

AU - Elliott, Richard

AU - Ashworth, Alan

AU - Lord, Christopher J

AU - Niculescu-Duvaz, Dan

AU - Porter, Roderick

AU - Boffey, Raymond

AU - Bayford, Melanie

AU - Firth-Clark, Stuart

AU - Jarvis, Ashley

AU - Perrior, Trevor R

AU - Key, Rebecca

PY - 2013/9/12

Y1 - 2013/9/12

N2 - The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3-aryl-5-substituted- 2H-isoquinolin-1-one compounds that, inter alia, inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.) and/or Wnt signalling. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to inhibit Wnt signalling; to treat disorders that are ameliorated by the inhibition of PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to treat disorders that are ameliorated by the inhibition of Wnt signalling; to treat proliferative conditions such as cancer, etc.(FR) La présente invention concerne d'une manière générale le domaine des composés thérapeutiques. Plus spécifiquement, la présente invention se rapporte à certains composés 3-aryl -5-substitué -2 H-isoquinolin -1-one qui, entre autres, inhibent PARP (par exemple, PARP1, TNKS1, TNKS2, etc.) et/ou de signalisation Wnt. La présente invention concerne également des compositions pharmaceutiques comprenant ces composés à la fois in vitro et in vivo pour inhiber la signalisation Wnt afin de traiter des troubles qui sont améliorés par l'inhibition de PARP (par exemple, PARP1, TNKS1, TNKS2, etc.), de traiter des troubles qui sont améliorés par l'inhibition de la signalisation Wnt et de traiter des états prolifératifs tels que le cancer, etc.

AB - The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3-aryl-5-substituted- 2H-isoquinolin-1-one compounds that, inter alia, inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.) and/or Wnt signalling. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to inhibit Wnt signalling; to treat disorders that are ameliorated by the inhibition of PARP (e.g., PARP1, TNKS1, TNKS2, etc.); to treat disorders that are ameliorated by the inhibition of Wnt signalling; to treat proliferative conditions such as cancer, etc.(FR) La présente invention concerne d'une manière générale le domaine des composés thérapeutiques. Plus spécifiquement, la présente invention se rapporte à certains composés 3-aryl -5-substitué -2 H-isoquinolin -1-one qui, entre autres, inhibent PARP (par exemple, PARP1, TNKS1, TNKS2, etc.) et/ou de signalisation Wnt. La présente invention concerne également des compositions pharmaceutiques comprenant ces composés à la fois in vitro et in vivo pour inhiber la signalisation Wnt afin de traiter des troubles qui sont améliorés par l'inhibition de PARP (par exemple, PARP1, TNKS1, TNKS2, etc.), de traiter des troubles qui sont améliorés par l'inhibition de la signalisation Wnt et de traiter des états prolifératifs tels que le cancer, etc.

M3 - Patent

M1 - WO2013132253

Y2 - 2013/03/07

PB - World Intellectual Property Organisation

ER -

3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE

Abstract / Description of output

Access to Document

Fingerprint

Cite this